Inside 340B Report

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including two new Centers for Medicare and Medicaid Services (CMS) final rules with major 340B implications; what the 2026 congressional midterm elections could mean for the future of 340B policy; and CVS Health's surprise move to split off its businesses into two companies. Ted also reflects on Inside 340B Report's 50th episode milestone and thanks the behind-the-scenes team that makes sure listeners can benefit from this show.   Key Topics Covered:   CMS Releases Final Rules Affecting 340B Will breaks down the new CMS rule to slash Medicare Part B reimbursement to certain types of 340B hospitals by around 32% starting next year. Ted looks back at the previous efforts to block the first Trump administration's Part B cuts and predicts there will be similar legal and legislative efforts this time as well. Will also explains CMS' other new rule creating a mandatory 340B data repository for Part D claims, including how it differs from other reporting requirements.   Congressional Bills and Midterm Outcomes Shannon, Luke and Ted discuss the outcomes of the historic midterm elections and what they could mean for 340B policy on Capitol Hill in 2027. Shannon highlights key races in the U.S. House, while Luke breaks down the results from the U.S. Senate. Ted offers insights into what 340B observers could expect to see happen on the policy front in the 120th Congress. The three also discuss two recently introduced federal bills that would halt the Trump administration's 340B rebate model pilot from taking effect as planned on Jan. 1, 2027.   CVS Breaks Up Will details CVS Health's recently announced move to split into two separate companies in 2028, and what that could mean for 340B stakeholders. He also notes that CVS' 340B practices have faced increasing scrutiny, including from a series of health system lawsuits alleging the company conspired to lower 340B contract pharmacy reimbursement owed to those hospitals. Will notes that CVS has denied those claims.   Subscribe & Stay Updated   How to Follow Us and Learn More About This Episode's Sponsor   Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.   This episode is brought to you by one of our great Ultra Diamond sponsors, Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship.     Subscribe to 340B Report with a Special Discount   We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including legal challenges and legislation that aim to stop the Trump administration's 340B rebate model pilot from taking effect in January. They also discuss the upcoming midterm elections, and what they could mean for 340B policy; a U.S. House Democrat priorities memo that includes 340B-related actions; and the controversy surrounding Amgen's new healthcare encounter and services claims data requirements. Key Topics Covered: Actions to Halt the 340B Rebate Model Pilot  Will breaks down the American Hospital Association (AHA)-led lawsuit seeking to block the Health Resources and Services Administration's (HRSA) 340B rebate pilot from taking effect on Jan. 1. He also discusses a federal judge's recent order allowing drug manufacturers to join the case as intervenors to defend the pilot. Meanwhile, Luke details the newly unveiled 340B Rebate Model Delay Act, a U.S. House bill which would delay the Trump administration's 340B rebate model pilot, or "any substantially similar" rebate program until Dec. 31, 2028. Midterm Elections  Shannon and Ted preview how the Nov. 3 midterm elections could affect 340B policy. Shannon notes the lawmakers up for reelection who serve on the U.S. House and Senate committees overseeing 340B—and who could be tapped to lead those panels depending on the election outcomes. Ted breaks down how election analysts expect the midterms to go for each party and how a close U.S. Senate race in Kansas could affect 340B policy on Capitol Hill in the next Congress. Shannon also discusses U.S. House Democrats' top healthcare priorities for the 120th Congress, including a September letter lawmakers sent to House Minority Leader Hakeem Jeffries (D-N.Y.) that called for immediate actions to bolster the 340B program and halt the Trump administration's 340B rebate model pilot. Amgen's New Requirements  Will details Amgen's new healthcare visit and service claims data requirements set to take effect in mid-November and explains why those requirements are more expansive than other drugmaker policies. Additionally, Luke discusses the National Association of Community Health Centers' letter asking HRSA to review the policy and direct Amgen to halt the requirements before they take effect next month. 340B Report's Midterm Webinar  Ted previews 340B Report's Nov. 10 subscriber-only webinar, which will dive into the midterm election results and what they mean for state and federal 340B policy in 2027 and beyond. He notes that the editorial team will also break down the major 340B changes on the horizon, including the latest news on the 340B rebate model and its legal challenges. Subscribers can learn more and register for the webinar by logging into 340B Report. Prospective subscribers can learn more about this exciting event by visiting 340B Report and taking advantage of a 25% discount on subscriptions. They can then benefit from all our must-watch webinars and other valuable services available only to subscribers. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, Verity Solutions. Verity Solutions' innovative, award-winning 340B program management solutions are designed to optimize 340B pharmacy spend and maximize pharmacy supply chain savings. We are very grateful to Verity Solutions for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including the newly-approved manufacturer 340B rebate pilot plans. They also discuss a new multi-organization community health center letter to Congressional leadership shared exclusively with 340B Report; the Pharmaceutical Research and Manufacturers of America's (PhRMA) new CEO; a 340B child site litigation update; and two 340B developments in the states. Key Topics Covered: HRSA's Rebate Pilot Plans  Will breaks down the Health Resources and Services Administration's (HRSA) recently approved manufacturer 340B rebate pilot plans. He also explains why two drugmakers may have chosen not to include their eligible drugs in the pilot. Meanwhile, Luke details a new letter from more than 50 community health center associations representing over 1,500 health centers asking certain U.S. House leaders to hold a hearing on the "impending implementation" of the 340B rebate model pilot. PhRMA's New Leader  Luke discusses PhRMA's new President and CEO Eric Cantor, who formerly served in Congress as the House Majority Leader for Republicans from 2011 to 2014.  Cantor was not active in 340B policy during his time on the Hill, but usually backed the drug industry in other policy areas. Ted provides his take on PhRMA's choice during the current political environment. 340B Child Site Ruling Appeal Will explains the latest in HRSA's appeal of a Washington, D.C., federal court ruling that struck down the agency's 340B hospital offsite clinic registration policy. He breaks down why the ruling was a victory for hospitals, as well as why both HRSA and PhRMA are arguing the ruling should be overturned. Will also discusses an amicus brief from four manufacturers taking a different approach. State 340B Updates Luke breaks down two new similar bills introduced in each chamber of the Pennsylvania legislature. Both bills would prohibit manufacturers from restricting delivery of 340B drugs to covered entities or their contract pharmacies and ban 340B claims data requirements not required under federal law, among other changes. Will then breaks down an Arkansas' federal judge's ruling in favor of that state's 340B contract pharmacy access law, and the history of that state's litigation. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, RxParadigm. RxParadigm's mission is to cultivate innovative approaches and technologies that promote transparency and authenticity, leading to enhanced outcomes, reduced overall healthcare costs and effective 340B program administration. We are very grateful to RxParadigm for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: 340B Report's scoop that the Trump administration is reportedly planning to shift 340B oversight to the U.S. Centers for Medicare and Medicaid Services (CMS); reactions to a proposal to slash Medicare Part B reimbursement for 340B hospitals; two major 340B legal developments; and a recap of 340B Report's latest webinar.  Key Topics Covered: Shifting 340B Oversight? Will details 340B Report's recent news alert reporting that the Trump administration plans to shift 340B oversight from its longtime home at the Health Resources and Services Administration (HRSA) to CMS this month. HRSA and CMS have not confirmed the report, which was based on a conversation with a source familiar with the plans. Will also explains why many 340B providers are concerned with the potential shift. Competing Takes on 340B Hospital Cuts Shannon discusses concerns 340B hospitals and New York congressional Republicans raised in public comments on CMS' proposed 2027 Hospital Outpatient Prospective Payment System rule, which would cut Medicare Part B reimbursement for 340B-acquired outpatient drugs. Meanwhile, Luke and Ted note that other stakeholders—including a private oncology practice group and a trade association of for-profit hospitals—have supported the move. 340B in the Courts Will breaks down two recent federal district court rulings dismissing manufacturer challenges to Colorado's 340B access law. He also shares an update on Sanofi's ongoing lawsuit against HRSA seeking providers' pharmacy services agreements. Will notes that HRSA has recently contacted multiple providers about these contracts, which Sanofi argues could reveal that covered entities transfer the title of 340B drugs to contract pharmacies in violation of the 340B statute. 340B Report's New Explainer Luke gives kudos to the editorial team on their recent webinar covering the 340B program's history and major tension points for both subscribers and nonsubscribers. He also discusses 340B Report's new explainer, which breaks down 340B program history, operations, oversight, key tension points and other important details. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, PharmaForce. PharmaForce is the only third-party administrator composed entirely of experienced 340B professionals developing uniquely flexible technology solutions for covered entities and pharmacies of every size. We are very grateful to PharmaForce for its sponsorship. Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: a key development in AbbVie's lawsuit challenging the Health Resources and Services Administration's (HRSA) 340B patient definition; potential candidates to become the next leader of an influential drug industry trade group; a new federal bill that would temporarily maintain 340B hospital eligibility; and the latest on the 340B rebate model pilot.   Key Topics Covered:   Providers Have a Say in Patient Definition Suit Will breaks down a Washington, D.C. federal judge's recent ruling allowing three national 340B provider groups to intervene inAbbVie's lawsuit challenging HRSA's 340B patient definition. He explains that, as intervenors, the groups will defend HRSA's definition and can participate in briefings and hearings, and potentially appeal any decisions. Will notes that the outcome of the case could have major 340B program implications, and discusses how it relates to a prior provider lawsuit involving HRSA's patient definition.    Who Will Lead PhRMA? Shannon discusses the former Republican policymakers Pharmaceutical Research and Manufacturers of America (PhRMA) is reportedly considering to replace its outgoing President and CEO Stephen Ubl. She notes that they include: former U.S. Reps. Greg Walden (R-Ore.), who previously chaired the House Energy and Commerce Committee, and Eric Cantor (R-Va.), former Louisiana Gov. Bobby Jindal (R) and former Centers for Medicare and Medicaid Services (CMS) Ad­min­is­tra­tor Seema Ver­ma. She and Ted reflect on the candidates' past records on 340B issues, while Ted offers some historical context on previous lawmakers that the big drug industry trade groups have selected to lead their organizations. He also speculates on what PhRMA might do this time.   New 340B Hospital Bill Luke details a new bill aimed at addressing hospital concerns that recent Medicaid cuts in the "big beautiful bill" could cause some hospitals to lose 340B eligibility. U.S. Rep. Hillary Scholten (D-Mich.) introduced the bill, which would temporarily maintain 340B eligibility for certain hospitals if their disproportionate share hospital (DSH) adjustment percentage falls below the required threshold.    Latest on the Rebate Model Will discusses the latest in HRSA's revised 340B rebate model pilot set to take effect on Jan. 1, 2027. He notes that drugmaker rebate plan applications were due Aug. 24, and that HRSA said it plans to announce approvals on Sept. 24. Will also speculates that any provider litigation challenging the rebate pilot is likely months away, as last year's successful hospital lawsuit was not filed until December 2025.    Subscribe & Stay Updated   How to Follow Us and Learn More About This Episode's Sponsor   Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.   This episode is brought to you by one of our great Ultra Diamond sponsors, NuvemRx. NuvemRx empowers covered entities to turn 340B from a compliance burden into a strategic asset with a full suite of TPA, in-house pharmacy and referral solutions. Learn more at www.nuvemrx.com. We are very grateful to NuvemRx for its sponsorship.    Subscribe to 340B Report with a Special Discount   We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest 340B news, including: the Health Resources and Services Administration's (HRSA) newly unveiled 340B rebate pilot; the introduction of the long-anticipated bipartisan Senate SUSTAIN 340B Act; and a new 340B Report analysis on how lower list prices are impacting 340B savings.    Key Topics Covered:   Rebate Model 2.0 Will breaks down the details of HRSA's revised 340B rebate pilot, which is scheduled to take effect Jan. 1, 2027, and apply to drugs subject to Medicare price negotiations for the 2026 and 2027 cycles. Shannon notes that provider groups panned the policy, arguing it would undermine their ability to serve vulnerable patients, while the drug industry praised it and say it is a step toward program transparency. Will explains that the new pilot appears on stronger legal footing than the agency's first attempt that was blocked in federal court. However, he notes, another lawsuit is still likely.    Meanwhile, On Capitol Hill Shannon discusses the long awaited Senate "Group of 6's" newly introduced SUSTAIN 340B Act. She notes that the 97-page bill would codify the use of contract pharmacies, end the 340B rebate model within one year and establish a neutral data clearinghouse, among other reforms..  Luke dives into his reporting on how stakeholders reacted to the bill and Ted provides information on what he is hearing from one of the key stakeholder groups.    Reduced WAC Prices Impacting Covered Entities Luke discusses his reporting on how lower wholesale acquisition costs (WAC) are impacting 340B revenue for covered entities. He explores how new policies, like the Medicare drug price negotiations and new Medicare inflationary penalties, are leading some drugmakers to lower their list prices, and in turn reducing providers' 340B savings. Luke notes that some covered entities have already seen a decrease of $1 million so far in 2026, which translated into less wraparound services for patients.    Subscribe & Stay Updated   How to Follow Us and Learn More About This Episode's Sponsor   Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.   This episode is brought to you by one of our great Ultra Diamond sponsors, CompassRx. CompassRx is the premier AI services platform built exclusively for 340B. Harnessing pharmacy and AI expertise, CompassRx helps maximize 340B savings and operational efficiency. Visit CompassRx.com to learn more. We are very grateful to CompassRx for its sponsorship.    Subscribe to 340B Report with a Special Discount   We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Editor-in-Chief Will Newton joins Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: a new Arkansas state lawsuit against 13 drugmakers and Second Sight Solutions; a key U.S. senator's recent comments on the program and new federal 340B lobbying data; and an update on the Health Resources and Services Administration's (HRSA) latest efforts to implement a controversial 340B rebate pilot.   Key Topics Covered:   Arkansas Files Suit Will breaks down Arkansas Attorney General Tim Griffin's (R) new lawsuit against 13 drugmakers and drug industry vendor Second Sight Solutions for allegedly violating the state's 340B access law. He details Griffin's press conference announcing the lawsuit, where he predicted it would become a "billion-dollar case" while surrounded by state 340B providers and advocates. Luke notes that AstraZeneca exempted Louisiana covered entities from its contract pharmacy restrictions after a court declined it and other drugmakers' request for a rehearing in a case relating to that state's contract pharmacy access law.   Meanwhile, On Capitol Hill Shannon discusses U.S. Sen. Bill Cassidy's (R-La.) latest comments on the 340B program during a recent Senate Health, Education, Labor and Pensions (HELP) Committee markup. Cassidy, a vocal 340B critic who chairs the HELP Committee, cautioned that an amended version of legislation to cap monthly insulin costs at $35 and create a pilot program to help states provide affordable insulin to uninsured patients could give "cover for 340B entities which are not using the [340B] program" the way Congress intended. Shannon also breaks down the latest 340B federal lobbying data, including what groups spent the most during the second quarter of 2026.   Rebate Model Update Will offers that it seems like a matter of when, not if, HRSA will release its new 340B rebate pilot notice. He notes that White House regulators recently held their last scheduled meeting on the proposal, which remains under regulatory review. Will also explains that providers continue to oppose 340B rebates and dispute HRSA's assessment of its burden. He then breaks down a recent federal appeals court decision that upheld HRSA's authority over 340B rebates, while rejecting drugmakers' claims that they could implement rebates without prior approval.   Subscribe & Stay Updated   How to Follow Us and Learn More About This Episode's Sponsor   Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.   This episode is brought to you by one of our great Ultra Diamond sponsors, Visante. Visante partners with health systems to deliver confidence in 340B—through deep experience, rigorous compliance and relentless focus on program compliance. We are very grateful to Visante for its sponsorship.    Subscribe to 340B Report with a Special Discount   We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Editor-in-Chief Will Newton, Managing Editor Shannon Young and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: a trio of congressional 340B proposals; potential steep Medicare Part B cuts for 340B hospitals; and a new provider lawsuit challenging Eli Lilly's move to cut off 340B pricing. Key Topics Covered: Three Major 340B Legislative Proposals Shannon, Luke and Ted discuss three new 340B-related proposals in Congress. Shannon breaks down U.S. Sen. Bill Cassidy's (R-La.) recently unveiled 340B discussion draft, which proposes several changes to the drug discount program that largely drew pushback from 340B provider advocates and support from the drug industry. Cassidy, who chairs the Senate Health, Education, Labor and Pensions (HELP) Committee, will leave Congress at the end of 2026. Shannon also discusses the U.S. House Ways & Means Committee's recent markup of a bill that would require certain hospitals to report 340B-related information on federal tax forms. Luke discusses a new bipartisan House bill that would also make several changes to the 340B program, but received mixed reactions from stakeholders. Ted offers insight on the various proposals, including how stakeholders have reacted to them.  CMS Eyes Steep Cuts for 340B Hospitals Will breaks down the Centers for Medicare & Medicaid Services' (CMS) proposal to cut Medicare Part B reimbursement for 340B hospitals by nearly 37%. He notes that CMS argues the effort will save taxpayers money, while hospitals contend it will undermine the 340B program's purpose of expanding access and services for vulnerable patients. Will also explains that CMS attempted to cut Part B reimbursement during the first Trump administration—before the U.S. Supreme Court unanimously overturned that effort on procedural grounds. Florida Hospital Sues Lilly Over 340B Data Reqs Will details a Florida teaching hospital's recent federal lawsuit challenging Lilly's move to cut off 340B pricing for failure to comply with the drugmaker's new 340B in-house pharmacy claims data requirements. He notes that more provider lawsuits are likely to follow, but explains that covered entities can face legal obstacles when attempting to directly sue drugmakers under 340B. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. This episode is brought to you by one of our great Ultra Diamond sponsors, Proximity. Proximity is the 340B revenue operations platform built to bring control back to your program. Proximity unifies and normalizes TPA, pharmacy, EHR, wholesaler and payer data into a single system—so issues can be identified, corrected and resolved across the full claim lifecycle. To learn more, reach out to [email protected]. We are very grateful to Proximity for its sponsorship.  Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: Eli Lilly's move to cut off 340B pricing for certain hospitals; the Health Resources and Services Administration's (HRSA) efforts to implement another rebate pilot, the government's decision to not appeal a key hospital purchasing policy court ruling and recent 340B activity in the states.   Key Topics Covered:   Lilly Cuts Off Non-Compliant Hospital 340B Pricing  Shannon and Ted discuss Lilly's decision to end 340B pricing for certain hospitals that failed to comply with its 340B in-house pharmacy claims data requirements and how hospital trade groups responded to that move. Shannon notes that while 340B Health and the American Hospital Association urged HRSA to step in, the agency said it was still determining its "next steps." Luke talks about possible actions states may take in response to Lilly's actions and other drugmakers' in-house claims data requirements. And Will notes that Vermont recently updated its state 340B law to protect covered entities in response to manufacturer in-house policies.    HRSA Takes Another Step Towards Rebate Pilot Will breaks down new HRSA regulatory documents and what they mean about a potential future 340B rebate pilot. He notes that HRSA is attempting to avoid the missteps that led federal courts to block the agency's original rebate pilot from taking effect. Will also explains that providers have disputed HRSA's estimate on the administrative burden of a rebate pilot, quoting a former HRSA official who argued it was "mind-boggling" that the agency hadn't changed its assessment.    Key State and Court Actions Shannon breaks down HRSA's decision not to appeal a Washington, D.C. federal district court's ruling to strike down a controversial 13-year-old policy that restricted how certain 340B hospitals can purchase initial drug inventory. She notes that while hospitals celebrated the move and its implications, the agency could still pursue the issue through regulation—or more likely—federal guidance. Ted offers background on the group purchasing organization (GPO) prohibition and the significance of HRSA's ruling.   Will discusses a federal court ruling that allowed Washington state's 340B contract pharmacy access law to take effect this month. He also provides an update on Illinois' pair of 340B bills that are currently awaiting action from the state's governor.   July Panel on Key 340B Developments   Join Verity Solutions for a panel discussion just ahead of the 340B Coalition Summer Conference. The complimentary event will take place July 13 from 8 to 9:15 a.m. ET at the Gaylord National Resort in National Harbor, Maryland. The event is open to all and separate from the Coalition Conference, so you need to register in advance. Learn more and register here.   Subscribe & Stay Updated   How to Follow Us and Learn More About This Episode's Sponsor   Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube.   Each episode is brought to you by one of our great Ultra Diamond sponsors, VytlOne. As the only independent provider of integrated pharmacy solutions, VytlOne leads the way in partnering with hospitals, health systems and health centers to unlock pharmacy revenue, strengthen local care and reinvest in communities. We are very grateful to VytlOne for its sponsorship.    Subscribe to 340B Report with a Special Discount   We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.

In this episode, 340B Report Publisher and CEO Ted Slafsky joins Associate Editors and Senior Writers Shannon Young and Will Newton and National Correspondent Luke Zarzecki in breaking down the latest in 340B news, including: Eli Lilly's 340B in-house claims data threat and a leading provider law firm's response; high-stakes oral arguments over two states' contract pharmacy laws; and the results from primaries involving high-profile 340B advocates. The team also recaps 340B Report's recent webinar on key 340B legal issues. Key Topics Covered: Lilly's In-House Claims Data Ultimatum  Luke highlights two recent letters sent to the Health Resources and Services Administration: one from Lilly and one from Hall Render, a law firm representing 340B providers. Lilly notified covered entities they had five days to comply with its 340B in-house pharmacy claims data submission policy, while Hall Render called for a U.S. Department of Health and Human Services Inspector General investigation into Lilly's requirements. Shannon notes that Sanofi recently announced 340B in-house claims data requirements, making it the ninth drugmaker to do so.  Latest Primary Results Shannon breaks down early results from June primary contests in California and South Dakota. She notes that U.S. Rep. Doris Matsui (D-Calif.), who is seen as a key 340B provider advocate in Congress, placed first in her primary. But, Shannon adds, she is likely to once again face off against a tough Democratic challenger, Mai Vang, in November. Shannon also discusses U.S. Rep. Dusty Johnson's (R-S.D.) third place finish in South Dakota's GOP gubernatorial primary, and how the loss of another key 340B leader on Capitol Hill could shape 340B policymaking in the next Congress. Oral Arguments and 340B Report Webinar Will discusses recent oral arguments on drugmaker challenges to Maine and Rhode Island's 340B contract pharmacy access laws before a Boston federal appeals court. He notes that one of the judges last year was a partner at a law firm where other partners were lobbying for a drug industry trade group against Maine's contract pharmacy bill before it became law. Will, Luke and Ted then break down the biggest takeaways from 340B Report's recent subscriber-only webinar, where two attorneys representing the covered entity and manufacturer perspectives joined 340B Report's editorial team to discuss the biggest 340B legal developments. Subscribe & Stay Updated How to Follow Us and Learn More About This Episode's Sponsor Stay tuned for more episodes every other week! 🎧Subscribe to Inside 340B Report on your favorite podcast platform or YouTube. Each episode is brought to you by one of our great Ultra Diamond sponsors, Pillr Health. Pillr is a leading provider of innovative solutions designed to optimize and streamline pharmacy operations with a focus on enhancing efficiency, reducing costs and improving patient outcomes, particularly within the 340B program. We are very grateful to Pillr Health for its sponsorship.  Subscribe to 340B Report with a Special Discount We're offering a special discount for podcast listeners. 340B Report is the indispensable source for news and intelligence on the 340B program. First-time subscribers may subscribe now using coupon code PODCAST25. Not ready to subscribe? Sign up for a 15-day free trial.